Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Serena Ruggieri

Showing results (71-80 of 104) with videos related to

Pageof 11
Sort By:
Journal of Neurology|November 24, 2016
Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naïve patients with multiple sclerosisLuca Prosperini, Francesco Saccà, Cinzia Cordioli, et al.
Neurology and Therapy|June 2, 2022
Predictors of Cladribine Effectiveness and Safety in Multiple Sclerosis: A Real-World, Multicenter, 2-Year Follow-Up StudyMaria Petracca, Serena Ruggieri, Elena Barbuti, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|August 4, 2025
Epilepsy in MS and its association with cognitive and psychological burdenValeria Pozzilli, Carla Tortorella, Luca Prosperini, et al.
International Journal of Molecular Sciences|May 27, 2023
Dynamic Evolution of Humoral and T-Cell Specific Immune Response to COVID-19 mRNA Vaccine in Patients with Multiple Sclerosis Followed until the Booster DoseSerena Ruggieri, Alessandra Aiello, Carla Tortorella, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|February 27, 2024
Treatment modifiers across different regimens of natalizumab treatment in MS: An Italian real-world experienceSerena Ruggieri, Antonio Ianniello, Massimiliano Copetti, et al.
Frontiers in Immunology|November 17, 2025
Minimal association between Th1-specific responses to COVID-19 vaccines and SARS-CoV-2 breakthrough infections in multiple sclerosis patients receiving disease-modifying therapiesAlessandra Aiello, Assunta Navarra, Shalom Haggiag, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 13, 2018
Impact of 3 Tesla MRI on interobserver agreement in clinically isolated syndrome: A MAGNIMS multicentre studyMarloes Hj Hagens, Jessica Burggraaff, Iris D Kilsdonk, et al.
Annals of Neurology|April 15, 2020
Longitudinal Assessment of Multiple Sclerosis with the Brain-Age ParadigmJames H Cole, Joel Raffel, Tim Friede, et al.
The Lancet. Neurology|December 26, 2017
Prediction of a multiple sclerosis diagnosis in patients with clinically isolated syndrome using the 2016 MAGNIMS and 2010 McDonald criteria: a retrospective studyMassimo Filippi, Paolo Preziosa, Alessandro Meani, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|December 15, 2022
Longitudinal characterisation of B and T-cell immune responses after the booster dose of COVID-19 mRNA-vaccine in people with multiple sclerosis using different disease-modifying therapiesAlessandra Aiello, Andrea Coppola, Serena Ruggieri, et al.
Pageof 11

Showing results (71-80 of 104) with videos related to

Sort By:
Pageof 11
Journal of Neurology|November 24, 2016
Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naïve patients with multiple sclerosisLuca Prosperini, Francesco Saccà, Cinzia Cordioli, et al.
Neurology and Therapy|June 2, 2022
Predictors of Cladribine Effectiveness and Safety in Multiple Sclerosis: A Real-World, Multicenter, 2-Year Follow-Up StudyMaria Petracca, Serena Ruggieri, Elena Barbuti, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|August 4, 2025
Epilepsy in MS and its association with cognitive and psychological burdenValeria Pozzilli, Carla Tortorella, Luca Prosperini, et al.
International Journal of Molecular Sciences|May 27, 2023
Dynamic Evolution of Humoral and T-Cell Specific Immune Response to COVID-19 mRNA Vaccine in Patients with Multiple Sclerosis Followed until the Booster DoseSerena Ruggieri, Alessandra Aiello, Carla Tortorella, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|February 27, 2024
Treatment modifiers across different regimens of natalizumab treatment in MS: An Italian real-world experienceSerena Ruggieri, Antonio Ianniello, Massimiliano Copetti, et al.
Frontiers in Immunology|November 17, 2025
Minimal association between Th1-specific responses to COVID-19 vaccines and SARS-CoV-2 breakthrough infections in multiple sclerosis patients receiving disease-modifying therapiesAlessandra Aiello, Assunta Navarra, Shalom Haggiag, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 13, 2018
Impact of 3 Tesla MRI on interobserver agreement in clinically isolated syndrome: A MAGNIMS multicentre studyMarloes Hj Hagens, Jessica Burggraaff, Iris D Kilsdonk, et al.
Annals of Neurology|April 15, 2020
Longitudinal Assessment of Multiple Sclerosis with the Brain-Age ParadigmJames H Cole, Joel Raffel, Tim Friede, et al.
The Lancet. Neurology|December 26, 2017
Prediction of a multiple sclerosis diagnosis in patients with clinically isolated syndrome using the 2016 MAGNIMS and 2010 McDonald criteria: a retrospective studyMassimo Filippi, Paolo Preziosa, Alessandro Meani, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|December 15, 2022
Longitudinal characterisation of B and T-cell immune responses after the booster dose of COVID-19 mRNA-vaccine in people with multiple sclerosis using different disease-modifying therapiesAlessandra Aiello, Andrea Coppola, Serena Ruggieri, et al.
Pageof 11